Physician profile
Mini Aggarwal
NPI 1588617401
$9,675.26
in general payments reported to CMS, 2019-2025
32 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $1,207 · 2021: $1,224 · 2022: $2,352 · 2023: $1,641 · 2024: $1,555 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,359 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,358.80 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,677.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $930.88 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $929.93 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $882.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $772.09 | 2022-2025 | |
| Pfizer INC. | $607.04 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.80 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $564.41 | 2019-2023 | Xarelto |
| Amgen INC. | $452.59 | 2019-2025 | Tepezza, Repatha, Otezla |
| Lilly USA, LLC | $410.97 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $232.25 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $196.71 | 2020-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Exact Sciences Corporation | $170.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Atricure, INC. | $156.25 | 2022 | |
| Esperion Therapeutics, INC. | $147.30 | 2020-2025 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $140.06 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $105.97 | 2021 | |
| Genzyme Corporation | $99.54 | 2022 | |
| Medtronic, INC. | $98.80 | 2024-2025 | Azure Xt Dr Mri Surescan, Symplicity G3 |
| Dexcom, INC. | $83.89 | 2022-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $82.11 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $79.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $60.26 | 2020-2025 | Zoryve |
| Sanofi Pasteur INC. | $39.40 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $29.98 | 2021-2023 | Contrave, Nexlizet, Nexletol |
| Phathom Pharmaceuticals, INC. | $28.88 | 2024 | Voquezna |
| Silk Road Medical, INC. | $25.32 | 2022 | |
| Dynavax Technologies Corporation | $18.31 | 2024 | Heplisav-B |
| Genentech USA, INC. | $17.14 | 2020 | |
| Dermira, INC. | $17.04 | 2020 | |
| Grifols USA, LLC | $16.58 | 2019 | |
| Cipher Pharmaceuticals US LLC | $16.30 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.